Six months after authorization, what do we know about Paxlovid?

See this article by RemedyOne EVP of clinical services Robert Louie as it originally appeared in Pharmaphorum.  It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with …

Six months after authorization, what do we know about Paxlovid? Read More »